Vertex Pharmaceuticals Incorporated with ticker code (VRTX) now have 25 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The target price High/Low ranges between $577.00 and $325.00 calculating the average target price we see $466.90. Now with the previous closing price of $418.82 this is indicating there is a potential upside of 11.5%. The 50 day moving average now sits at $407.88 and the 200 day MA is $385.67. The company has a market cap of 108.12B. The stock price for the company is currently $418.99 USD
The potential market cap would be $120,533,844,139 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 27.17, revenue per share of $39.49 and a 12.82% return on assets.
Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on developing medicines that treat the underlying cause of cystic fibrosis (CF). Its pipeline includes mid- and late-stage clinical programs in sickle cell disease, beta thalassemia, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, and alpha-1 antitrypsin deficiency, and earlier-stage programs in diseases such as muscular dystrophies. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). The Company has a pipeline of investigational small molecule, cell and genetic therapies in other serious diseases where it has deep insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, pain, type 1 diabetes, alpha-1 antitrypsin deficiency and Duchenne muscular dystrophy.
